TSE:AUPAurinia Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Aurinia Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add C$21.18 -0.71 (-3.24 %) (As of 05/28/2020 04:00 PM ET) Add Compare Share Today's RangeC$21.07Now: C$21.18▼C$21.9350-Day RangeC$20.31MA: C$22.89▼C$25.7452-Week RangeC$4.70Now: C$21.18▼C$28.59Volume122,365 shsAverage Volume170,737 shsMarket CapitalizationC$2.38 billionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsInsider TradesHeadlinesSocial Media Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of autoimmune diseases in Canada, the United States, China, and Switzerland. The company is developing voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis. It has a sales agreement with Cantor Fitzgerald & Co.; and a manufacturing collaboration and services agreement with Lonza Ltd. The company was formerly known as Isotechnika Pharma Inc. and changed its name to Aurinia Pharmaceuticals Inc. in October 2013. Aurinia Pharmaceuticals Inc. was founded in 1993 and is headquartered in Victoria, Canada.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Aurinia Pharmaceuticals. Previous Next 2.8 Community Rank Outperform VotesAurinia Pharmaceuticals has received 241 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAurinia Pharmaceuticals has received 189 “underperform” votes. (Add your “underperform” vote.)Community SentimentAurinia Pharmaceuticals has received 56.05% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Aurinia Pharmaceuticals and other stocks. Vote “Outperform” if you believe AUP will outperform the S&P 500 over the long term. Vote “Underperform” if you believe AUP will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAurinia Pharmaceuticals does not currently pay a dividend.Dividend GrowthAurinia Pharmaceuticals does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aurinia Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought C$0.00 in company stock and sold C$402,896.00 in company stock. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Aurinia Pharmaceuticals are expected to grow in the coming year, from C($0.24) to C$0.00 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aurinia Pharmaceuticals is -16.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aurinia Pharmaceuticals is -16.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAurinia Pharmaceuticals has a P/B Ratio of 9.04. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.69 out of 5 stars Industry, Sector and Symbol Stock Exchange TSE Industry Technical & System Software Sub-IndustryN/A SectorComputer and Technology Current SymbolTSE:AUP Previous SymbolTSE:ISA CUSIPN/A CIKN/A Webwww.auriniapharma.com Phone+1-250-7084272Debt Debt-to-Equity Ratio2.22 Current Ratio21.01 Quick Ratio20.43Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesC$318,000.00 Price / Sales7,496.39 Cash FlowC$2.45 per share Price / Cash Flow8.64 Book ValueC$2.34 per share Price / Book9.04Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees39 Outstanding Shares112,552,000Market CapC$2.38 billion Next Earnings Date8/4/2020 (Estimated) OptionableNot Optionable TSX:AUP Rates by TradingView Receive AUP News and Ratings via Email Sign-up to receive the latest news and ratings for AUP and its competitors with MarketBeat's FREE daily newsletter. Aurinia Pharmaceuticals (TSE:AUP) Frequently Asked Questions How has Aurinia Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)? Aurinia Pharmaceuticals' stock was trading at C$19.38 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, AUP stock has increased by 9.3% and is now trading at C$21.18. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Aurinia Pharmaceuticals? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aurinia Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Aurinia Pharmaceuticals. When is Aurinia Pharmaceuticals' next earnings date? Aurinia Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Aurinia Pharmaceuticals. How were Aurinia Pharmaceuticals' earnings last quarter? Aurinia Pharmaceuticals Inc (TSE:AUP) released its quarterly earnings results on Thursday, March, 5th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.27) by $0.12. The firm had revenue of $0.04 million for the quarter, compared to the consensus estimate of $0.05 million. View Aurinia Pharmaceuticals' earnings history. Has Aurinia Pharmaceuticals been receiving favorable news coverage? News coverage about AUP stock has trended extremely positive recently, according to InfoTrie. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Aurinia Pharmaceuticals earned a coverage optimism score of 4.7 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 4.0 out of 10, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near term. View the latest news aboutAurinia Pharmaceuticals. Who are some of Aurinia Pharmaceuticals' key competitors? Some companies that are related to Aurinia Pharmaceuticals include Iress (IRE), Micro Focus International (MCRO), GB Group (GBG), Emis Group (EMIS), Absolute Software (ABT), SDL (SDL), Ideagen (IDEA), Computer Modelling Group (CMG), Tecsys (TCS), Dotdigital Group (DOTD), Wandisco (WAND), Microgen (MCGN), Covata (CVT), IDOX (IDOX) and Eckoh (ECK). View all competitors. What other stocks do shareholders of Aurinia Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aurinia Pharmaceuticals investors own include ARC Resources (ARX), Aurinia Pharmaceuticals (AUPH), Enbridge (ENB), Aurora Cannabis (ACB), Allena Pharmaceuticals (ALNA), Brookfield Renewable Partners (BEP.UN), Costco Wholesale (COST), Keysight Technologies (KEYS), Surge Energy (SGY) and Algonquin Power & Utilities (AQN). Who are Aurinia Pharmaceuticals' key executives? Aurinia Pharmaceuticals' management team includes the following people: Dr. Richard M. Glickman, Founder, Chairman, Pres & CEO (Age 61)Mr. Michael R. Martin, Co-Founder & COOMr. Dennis Bourgeault CPA, C.A., CFO & Sec.Mr. Robert B. Huizinga RN NNC, MSc(Epi), CNeph(C), Exec. VP of Corp. Devel.Dr. Neil Solomons M.D., Chief Medical Officer What is Aurinia Pharmaceuticals' stock symbol? Aurinia Pharmaceuticals trades on the Toronto Stock Exchange (TSX) under the ticker symbol "AUP." How do I buy shares of Aurinia Pharmaceuticals? Shares of AUP and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade, and Charles Schwab. What is Aurinia Pharmaceuticals' stock price today? One share of AUP stock can currently be purchased for approximately C$21.18. How big of a company is Aurinia Pharmaceuticals? Aurinia Pharmaceuticals has a market capitalization of C$2.38 billion and generates C$318,000.00 in revenue each year. Aurinia Pharmaceuticals employs 39 workers across the globe. What is Aurinia Pharmaceuticals' official website? The official website for Aurinia Pharmaceuticals is www.auriniapharma.com. How can I contact Aurinia Pharmaceuticals? Aurinia Pharmaceuticals' mailing address is 1203-4464 Markham St, VICTORIA, BC V8Z 7X8, Canada. The company can be reached via phone at +1-250-7084272. This page was last updated on 5/28/2020 by MarketBeat.com Staff
